N-benzyl-N-ethyl-2-(3,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyridine-3-acetamide | 1283074-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-benzyl-N-ethyl-2-(3,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyridine-3-acetamide
• 英文别名: N-benzyl-2-[2-(3,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl]-N-ethylacetamide
• CAS: 1283074-11-2
• 化学式: C₂₅H₂₃Cl₂N₃O
• 分子量: 452.383
• InChiKey: OBCXJDCPGARBPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  37.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 2-Aryl Imidazo[1,2-a]Pyridine-3-Acetamide Derivatives, Preparation Methods and Uses Thereof
  申请人：Yang Rifang

  公开号：US20130203754A1

  公开（公告）日：2013-08-08

  Disclosed are 2-arylimidazo[1,2- a ]pyridine-3-acetamide derivatives represented by formula I, their tautomer, racemate or optical isomer, their pharmaceutically acceptable salt, or their solvates, wherein R 1 , R 2 , R 3 and R 4 are defined as in the specification. Preparation methods of said compounds and use of said compounds in treating and/or preventing central nervous system disease associated with TSPO functional disorder

  公开了由式I表示的2-芳基咪唑并[1,2-a]吡啶-3-乙酰胺衍生物，它们的互变体、消旋体或光学异构体，它们的药学上可接受的盐，或它们的溶剂合物，其中R1、R2、R3和R4如规范中定义。所述化合物的制备方法以及所述化合物在治疗和/或预防与TSPO功能紊乱相关的中枢神经系统疾病中的用途。
• 2-ARYL IMIDAZO[1,2-A]PYRIDINE-3-ACETAMIDE DERIVATIVES, PREPARATION METHODS AND USE THEREOF
  申请人：Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China

  公开号：EP2586780B1

  公开（公告）日：2017-03-22
• US8980887B2
  申请人：——

  公开号：US8980887B2

  公开（公告）日：2015-03-17
• [EN] 2-ARYL IMIDAZO[1,2-A]PYRIDINE-3-ACETAMIDE DERIVATIVES, PREPARATION METHODS AND USE THEREOF<br/>[FR] DÉRIVÉS DU 2-ARYL IMIDAZO[1,2-?]PYRIDINE-3-ACÉTAMIDE, LEURS MÉTHODES DE PRÉPARATION ET UTILISATION
  申请人：INST PHARM & TOXICOLOGY AMMS

  公开号：WO2011160548A1

  公开（公告）日：2011-12-29

  Disclosed are 2-aryl imidazo[1,2-a]pyridine-3-acetamide derivatives represented by formula I, their tautomers, racemates or optical isomers, their pharmaceutically acceptable salts or their solvates, wherein R1, R2, R3 and R4 are defined as in the specification. Preparation methods of said compounds and use of said compounds in treating and/or preventing central nervous system diseases associated with TSPO functional disorders are also disclosed.